PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance
Thoracic Cancer · 2026
DOI: 10.1111/1759-7714.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Toshiyuki Sumi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor‐mutated (EGFRm) non‐small cell lung cancer (NSCLC) responds well to EGFR tyrosine kinase inhibitors (EGFR‐TKIs), yet optimal therapy after resistance remains uncertain. Although immune checkpoint inhibitors (ICIs) show limited overall efficacy, heterogeneity in response by programmed cell death ligand 1 (PD‐L1) expression exists.
Methods
We retrospectively evaluated 90 patients with advanced/recurrent EGFRm NSCLC treated with first‐line EGFR‐TKIs (October 2018–October 2023). Clinicopathological and radiologic features were compared by PD‐L1 tumor proportion score (< 50% vs. ≥ 50%). The primary analysis evaluated overall survival from first progression (post‐progression OS/PPS) using a time‐varying Cox model with start–stop intervals, modeling ICI as a time‐dependent exposure ICI( t ) and testing the ICI( t ) × PD‐L1 interaction.
Results
The PD‐L1 ≥ 50% group ( n = 26) more often had solid histology (62% vs. 8%), solid nodules on computed tomography (96% vs. 52%), and larger tumors (median 42.0 vs. 27.5 mm). Among 68 patients evaluable from t 0 , the ICI( t ) × PD‐L1 interaction was significant (Wald p = 0.015; likelihood‐ratio p = 0.036). Stratum‐specific adjusted ICI effects suggested a detrimental association in PD‐L1 < 50% (hazard ratio [HR]: 3.11, 95% confidence interval [CI]: 0.94–10.30) but favorable association in PD‐L1 ≥ 50% (HR: 0.457, 95% CI: 0.138–1.512). In exploratory analyses of 22 ICI‐treated patients, PD‐L1 ≥ 50% showed higher response rates (64% vs. 9%) and longer time to treatment failure (3.4 vs. 1.4 months).
Conclusions
High PD‐L1 expression in EGFRm NSCLC is associated with more aggressive morphologic features and modifies the association between post‐progression ICI and survival. These findings support PD‐L1‐informed selection after EGFR‐TKI failure, while prospective confirmation is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan.
- Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Surgical Pathology, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan.
ORCID-Profile: Toshiyuki Sumi
Zitieren
APA
Sumi, T., Ishigooka, T., Matsuura, K., Ikeda, T., Yamada, Y., Arioka, K., & Chiba, H. (2026). PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70252
Vancouver
Sumi T, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Arioka K, et al. PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70252
BibTeX
@article{Sumi2026,
author = {Sumi, Toshiyuki and Ishigooka, Taiki and Matsuura, Keigo and Ikeda, Takumi and Yamada, Yuichi and Arioka, Kotomi and Chiba, Hirofumi},
title = {PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance},
journal = {Thoracic Cancer},
year = {2026},
doi = {10.1111/1759-7714.70252}
}
EUVIMED